September 30, 2022
Rose
The list price of the therapy, Relyvrio, is much higher than an economic research group recommends, but the company says most patients will pay very little themselves.
from NYT > Health https://ift.tt/dLgV1XA
September 30, 2022
Rose
Health - The New York Times, NYT > Health
No comments
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment